ArticleInfection and drug resistance2025
Clinical Characteristics and Treatment Outcomes of Pediatric Drug-Resistant
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association of doxycycline treatment with time to first documented MP-RNA negative conversion in pediatric Mycoplasma pneumoniae pneumonia: a retrospective cohort study.Italian journal of pediatrics · 2026Article
- Explainable machine learning for diagnosing severeFrontiers in pediatrics · 2026Article
- Host inflammatory markers and MLVA profiling for risk assessment of severe pediatricFrontiers in cellular and infection microbiology · 2026Article
- Mycoplasma pneumoniae in hospitalised children in the post-COVID era: clinical outcomes from a Turkish multicenter cohort.European journal of pediatrics · 2025Article
- A machine learning-based predictive model for multilobar pulmonary consolidation induced by macrolide-resistantMicrobiology spectrum · 2025Article
- Clinical characteristics of mycoplasma pneumoniae pneumonia in children with 23 S rRNA mutations in domain V and exploration of the timing of glucocorticoid therapy.BMC infectious diseases · 2025Article
- Development and validation of a nomogram for early prediction of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objective: This study examined the clinical characteristics of MUMPP and the effects of various treatments on children with MUMPP during March 2023 to February 2024 in southern China. Methods: We conducted a retrospective case-control study at a university-affiliated hospital in southern China. Patients were categorized based on their response to macrolide treatment into two groups: MUMPP and control group. The study included 549 pediatric patients. Of these, 297 were in the MUMPP group and 252 were in the control group. This categorization allowed us to compare clinical characteristics and laboratory indicators between the groups. The MUMPP group received one of the three treatments: combined antibiotics, additional steroids, or a switch to doxycycline. Subsequently, we analyzed differences in clinical outcomes, which included hospital stay, hospital cost, and recovery time. Results: No significant differences were found in gender or pre-admission disease duration between the MUMPP and control group (P>0.05). However, subjects in MUMPP group was older, had longer fever durations, extended hospital stays, higher medical costs, and elevated levels of C-reactive protein, lactate dehydrogenase, IL-6, and γ-IFN. All of which showed statistically significant differences (P<0.05). Within the MUMPP group, patients switched to doxycycline had the shortest hospital stay and recovery time, significantly differing from those in other treatment groups (P<0.05). Conclusion: Children in the MUMPP group exhibited higher inflammatory indicators than the control group. The early adaptation of treatment strategies, particularly the switch to doxycycline, is associated with improved clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.